HSB-3215 / Canton Strategic Holdings - LARVOL DELTA

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology (Streetinsider.com) - "Tharimmune, Inc...announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Programmed Death-1 (PD-1) and Vascular Endothelial Growth Factor (VEGF), and HS3215, a dual-target biologic binding to Human Epidermal Growth Factors 2 (HER2) and 3 (HER3) receptors....Tharimmune plans to further optimize and improve binding characteristics of HS1940 and present more data at future scientific conferences. The Company expects to initiate IND-enabling studies for HS1940 in 2025."

Preclinical • Oncology • Solid Tumor

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 (GlobeNewswire) - "Hillstream BioPharma, Inc...today announced the expansion of its collaboration with Minotaur Therapeutics, Inc. ('Minotaur') and its license agreement with OmniAb, Inc. ('OmniAb') to advance the development of next generation targeted Knob biologics (Picobodies^TM) against HER3 and a new undisclosed oncology target. Hillstream will collaborate with Minotaur using OmniAb’s 'OmniTaur' technology to discover targeted biotherapeutic Picobodies complementing Hillstream’s most advanced program, HSB-3215, a HER2/HER3 bispecific antibody (BsAb)."

Licensing / partnership • Oncology • Solid Tumor

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics (GlobeNewswire) - "Hillstream will focus its pipeline on advancing novel oncology assets with the greatest potential and strong competitive profiles to address unmet needs across multiple solid tumors, such as bispecific antibodies and ADCs targeting novel conformational epitopes on high value validated targets, HER2 and HER3, with a more potent Bystander Effect...The Company intends to develop this novel BsAb and file an IND application with the US FDA late next year...Hillstream also intends to further enhance its previously announced collaborations with Applied Biomedical Science Institute (ABSI) and Minotaur to develop novel bovine-derived biologics in multiple formats against highly validated targets, including PD-1, HER2 and TROP-2, referred to as PicoKnobsTM. An update regarding these collaborations will be announced during an R&D Day in the third quarter."

Commercial • IND • Oncology • Solid Tumor

Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023 (GlobeNewswire) - "Hillstream BioPharma, Inc...announced that its CEO Randy Milby will be participating – in person – at two major industry conferences in April 2023....Mr. Milby will also discuss recent operational highlights, and updates on its immuno-oncology pipeline candidates, including: Its lead drug candidate HSB-1216, utilizing ferroptosis, and the outlook for initiating a clinical study in the second half of 2023. The Company’s emerging immune-oncology pipeline led by HSB-3215 which is an anti-HER2 monoclonal antibody."

New trial • Preclinical • Oncology